We are live on
!
Find out more
LCS
Levin Capital Strategies Portfolio holdings
AUM
$1.49B
1-Year Est. Return
30.44%
This Fund
S&P 500
This Quarter
Est. Return
+2.39%
1 Year Est. Return
+30.44%
3 Year Est. Return
+88.59%
5 Year Est. Return
+121.06%
10 Year Est. Return
+327.09%
AUM
$5.56B
AUM Growth
–
Cap. Flow
+$5.58B
Cap. Flow
% of AUM
100.52%
Top 10 Holdings %
Top 10 Hldgs %
34.75%
Holding
318
New
318
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$284M |
| 2 |
Eaton
ETN
|
+$281M |
| 3 |
Citigroup
C
|
+$238M |
| 4 |
PG&E
PCG
|
+$193M |
| 5 |
Molson Coors Class B
TAP
|
+$173M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.42% |
| 2 | Healthcare | 16.25% |
| 3 | Technology | 12.9% |
| 4 | Consumer Staples | 12.08% |
| 5 | Industrials | 11.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eaton
ETN
$152B
| $293M | 5.28% |
+4,456,178
| New | +$281M |
|
|
2
Pfizer
PFE
$157B
| $273M | 4.91% |
+10,274,072
| New | +$284M |
|
|
3
Citigroup
C
$228B
| $238M | 4.28% |
+4,957,577
| New | +$238M |
|
|
4
PG&E
PCG
$29B
| $191M | 3.45% |
+4,186,905
| New | +$193M |
|
5
Medtronic
MDT
$120B
| $170M | 3.06% |
+3,298,045
| New | +$163M |
|
|
6
Molson Coors Class B
TAP
$7.32B
| $163M | 2.94% |
+3,415,755
| New | +$173M |
|
7
Qualcomm
QCOM
$201B
| $154M | 2.77% |
+2,521,297
| New | +$161M |
|
8
Apple
AAPL
$4.84T
| $153M | 2.76% |
+10,822,476
| New | +$166M |
|
|
CIT
9
DELISTED
CIT Group Inc.
CIT
| $148M | 2.67% |
+3,177,398
| New | +$140M |
|
|
DD
10
DELISTED
Du Pont De Nemours E I
DD
| $146M | 2.63% |
+2,935,975
| New | +$148M |
|
11
Merck
MRK
$355B
| $132M | 2.38% |
+2,979,555
| New | +$133M |
|
12
Occidental Petroleum
OXY
$63.5B
| $130M | 2.35% |
+1,524,343
| New | +$129M |
|
13
Target
TGT
$70.1B
| $123M | 2.22% |
+1,791,923
| New | +$125M |
|
14
Wells Fargo
WFC
$271B
| $121M | 2.17% |
+2,920,494
| New | +$114M |
|
15
MetLife
MET
$62.4B
| $111M | 1.99% |
+2,709,996
| New | +$99.7M |
|
16
JPMorgan Chase
JPM
$937B
| $109M | 1.96% |
+2,061,657
| New | +$105M |
|
|
RDS.A
17
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $99.3M | 1.79% |
+1,667,131
| New | +$103M |
|
18
Verizon
VZ
$214B
| $93M | 1.67% |
+1,846,622
| New | +$94.2M |
|
|
EMC
19
DELISTED
EMC CORPORATION
EMC
| $91.7M | 1.65% |
+3,881,126
| New | +$91.5M |
|
|
SFD
20
DELISTED
SMITHFIELD FOODS,INC
SFD
| $88.6M | 1.59% |
+2,705,571
| New | +$76.6M |
|
21
Bio-Rad Laboratories Class A
BIO
$10.1B
| $82.7M | 1.49% |
+736,879
| New | +$86.4M |
|
22
Oracle
ORCL
$404B
| $81.7M | 1.47% |
+2,661,434
| New | +$88.3M |
|
|
PF
23
DELISTED
Pinnacle Foods, Inc.
PF
| $75.2M | 1.35% |
+3,114,537
| New | +$75.8M |
|
24
Conagra Brands
CAG
$7.21B
| $72.2M | 1.3% |
+2,657,624
| New | +$71.9M |
|
25
Microsoft
MSFT
$3.69T
| $69.9M | 1.26% |
+2,022,495
| New | +$66.3M |
|
Similar funds
ACB
MFWP
FCM
PMG
RG
TIA
MM
WA
Levin Capital Strategies's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for Levin Capital Strategies, which disclosed 318 positions worth $5.56B. Its ten largest holdings account for 35% of the portfolio.
Its largest position is Pfizer: 10,274,072 shares worth $273M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, followed by Healthcare and Technology.
- Levin Capital Strategies's largest Q2 2013 buy was Pfizer: 10,274,072 shares worth $273M.
- Levin Capital Strategies's ten largest holdings make up 35% of its $5.56B portfolio in Q2 2013.
- Levin Capital Strategies disclosed 318 positions in Q2 2013, its first 13F filing on record.
Based on Levin Capital Strategies's 13F filing for Q2 2013, filed 13 Aug 2013.